HOME >> MEDICINE >> NEWS
NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks

The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is restructuring its HIV/AIDS clinical trials networks and soliciting investigators and institutions to lead the reorganized effort. This reorganization, designed in response to both the changing face of the AIDS epidemic and evolving scientific challenges, will enable NIAID and its many collaborators to effectively continue their research for safe, effective and affordable drugs, preventive strategies and HIV vaccines. The new network leadership that will be established through this process will direct, coordinate and conduct NIAID-funded HIV/AIDS clinical research both domestically and internationally. NIAID, part of the National Institutes of Health (NIH), supports the world's largest portfolio of clinical research in HIV prevention, vaccine and treatment.

"This clinical leadership solicitation reflects our vision to improve coordination, collaboration and flexibility in NIAID-supported HIV/AIDS prevention, vaccine and treatment research," says NIAID Director Anthony S. Fauci, M.D. "The current NIAID AIDS research structure was critical to the discovery of antiretrovirals to treat HIV-1 in adults and children; the development of strategies to successfully prevent mother-to-child HIV transmission; and the significant progress in the global search for an AIDS vaccine. This newly designed clinical research structure will now provide us with the opportunity to build on those successes and address future global research challenges."

The leadership solicitation, known as a Request for Applications (RFA), is now available for review by interested parties on the NIAID Web site (see below for details). A second RFA, to be released in early 2005, will solicit applications for the Clinical Trial Units (CTUs) that will implement the research plans of the networks. Funding for the two RFAs is expected to total up to $300 million for the first year, and funding may conti
'"/>

Contact: NIAID Press Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
1-Dec-2004


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID launches influenza genome sequencing project
6. NIAID launches program to improve medical tools against emerging infectious diseases
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... November 22, 2014 The Sports Conflict ... Roy Baroff to its team of conflict resolution professionals. ... player, coach, and referee. He has over 30 years experience ... beyond. , “I'm very excited to connect with SCI and ... related interests to a program with a complete sports focus,” ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
(Date:11/21/2014)... Nov. 21, 2014 In September 2014, the ... carried out a new product development plan that started ... "limited edition" lab coat , aptly named "Vera ... surgery in the world. The new women,s designer lab ... with a sleek envelope collar, vertical princess and high ...
(Date:11/21/2014)... , Nov. 21, 2014  PTC Therapeutics, Inc. (NASDAQ: ... 2014 Legend of Technology Award for Vision, Innovation, and Leadership ... Chief Executive Officer. This award recognizes an individual who has ... New Jersey for several decades. ... Award," stated Stuart Peltz , Ph.D., CEO of PTC ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
Cached News: